These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

299 related items for PubMed ID: 29756998

  • 21. Unveiling ficolins: diagnostic and prognostic biomarkers linked to the Tumor Microenvironment in Lung Cancer.
    Zhang Z, Geng X, Yin M, Zhang S, Liu Y, Hu D, Zheng G.
    World J Surg Oncol; 2024 Oct 10; 22(1):273. PubMed ID: 39390580
    [Abstract] [Full Text] [Related]

  • 22. Exploring and comparing of the gene expression and methylation differences between lung adenocarcinoma and squamous cell carcinoma.
    Yang Y, Wang M, Liu B.
    J Cell Physiol; 2019 Apr 10; 234(4):4454-4459. PubMed ID: 30317601
    [Abstract] [Full Text] [Related]

  • 23. High Expression of FGF5 Is an Independent Prognostic Factor for Poor Overall Survival and Relapse-Free Survival in Lung Adenocarcinoma.
    Zhao T, Qian K, Zhang Y.
    J Comput Biol; 2020 Jun 10; 27(6):948-957. PubMed ID: 31553229
    [Abstract] [Full Text] [Related]

  • 24. NFIX downregulation independently predicts poor prognosis in lung adenocarcinoma, but not in squamous cell carcinoma.
    Ge J, Dong H, Yang Y, Liu B, Zheng M, Cheng Q, Peng L, Li J.
    Future Oncol; 2018 Dec 10; 14(30):3135-3144. PubMed ID: 30418046
    [Abstract] [Full Text] [Related]

  • 25. Elevated FAM83A expression predicts poorer clincal outcome in lung adenocarcinoma.
    Zhang J, Sun G, Mei X.
    Cancer Biomark; 2019 Dec 10; 26(3):367-373. PubMed ID: 31594212
    [Abstract] [Full Text] [Related]

  • 26. A prognosis-related molecular subtype for early-stage non-small lung cell carcinoma by multi-omics integration analysis.
    Yang K, Wu Y.
    BMC Cancer; 2021 Feb 06; 21(1):128. PubMed ID: 33549049
    [Abstract] [Full Text] [Related]

  • 27. Differential prognostic impact and potential molecular mechanisms of PCDHGA12 expression in lung adenocarcinoma and squamous cell carcinoma.
    Xu X, Zhang J, Yao T, Zhao X, Wu Q, Lu C, Guo X, Xie S, Qiu L, Bi R, Xue H.
    Int Immunopharmacol; 2024 Sep 30; 139():112727. PubMed ID: 39067405
    [Abstract] [Full Text] [Related]

  • 28. GPC3 affects the prognosis of lung adenocarcinoma and lung squamous cell carcinoma.
    Ning J, Jiang S, Li X, Wang Y, Deng X, Zhang Z, He L, Wang D, Jiang Y.
    BMC Pulm Med; 2021 Jun 10; 21(1):199. PubMed ID: 34112123
    [Abstract] [Full Text] [Related]

  • 29. The value of CEP55 gene as a diagnostic biomarker and independent prognostic factor in LUAD and LUSC.
    Fu L, Wang H, Wei D, Wang B, Zhang C, Zhu T, Ma Z, Li Z, Wu Y, Yu G.
    PLoS One; 2020 Jun 10; 15(5):e0233283. PubMed ID: 32437446
    [Abstract] [Full Text] [Related]

  • 30. Association of TOP2A and ADH1B with lipid levels and prognosis in patients with lung adenocarcinoma and squamous cell carcinoma.
    Yin D, Zhang Y, Li H, Cheng L.
    Clin Respir J; 2023 Dec 10; 17(12):1301-1315. PubMed ID: 37985446
    [Abstract] [Full Text] [Related]

  • 31. Cancer Stemness-Based Prognostic Immune-Related Gene Signatures in Lung Adenocarcinoma and Lung Squamous Cell Carcinoma.
    Li N, Li Y, Zheng P, Zhan X.
    Front Endocrinol (Lausanne); 2021 Dec 10; 12():755805. PubMed ID: 34745015
    [Abstract] [Full Text] [Related]

  • 32. USP4 expression independently predicts favorable survival in lung adenocarcinoma.
    Zhong M, Jiang Q, Jin R.
    IUBMB Life; 2018 Jul 10; 70(7):670-677. PubMed ID: 29667299
    [Abstract] [Full Text] [Related]

  • 33. WIF-1 and Ihh Expression and Clinical Significance in Patients With Lung Squamous Cell Carcinoma and Adenocarcinoma.
    Zhang Y, Hu C.
    Appl Immunohistochem Mol Morphol; 2018 Aug 10; 26(7):454-461. PubMed ID: 27801732
    [Abstract] [Full Text] [Related]

  • 34. Lung adenocarcinoma and lung squamous cell carcinoma cancer classification, biomarker identification, and gene expression analysis using overlapping feature selection methods.
    Chen JW, Dhahbi J.
    Sci Rep; 2021 Jun 25; 11(1):13323. PubMed ID: 34172784
    [Abstract] [Full Text] [Related]

  • 35. High KIF2A expression promotes proliferation, migration and predicts poor prognosis in lung adenocarcinoma.
    Xie T, Li X, Ye F, Lu C, Huang H, Wang F, Cao X, Zhong C.
    Biochem Biophys Res Commun; 2018 Feb 26; 497(1):65-72. PubMed ID: 29427669
    [Abstract] [Full Text] [Related]

  • 36. Epigenetic loss of putative tumor suppressor SFRP3 correlates with poor prognosis of lung adenocarcinoma patients.
    Schlensog M, Magnus L, Heide T, Eschenbruch J, Steib F, Tator M, Kloten V, Rose M, Noetzel E, Gaisa NT, Knüchel R, Dahl E.
    Epigenetics; 2018 Feb 26; 13(3):214-227. PubMed ID: 27623992
    [Abstract] [Full Text] [Related]

  • 37. Overexpression of Family with Sequence Similarity 83, Member A (FAM83A) Predicts Poor Clinical Outcomes in Lung Adenocarcinoma.
    Zhang JT, Lin YC, Xiao BF, Yu BT.
    Med Sci Monit; 2019 Jun 08; 25():4264-4272. PubMed ID: 31175804
    [Abstract] [Full Text] [Related]

  • 38. A large cohort study identifying a novel prognosis prediction model for lung adenocarcinoma through machine learning strategies.
    Li Y, Ge D, Gu J, Xu F, Zhu Q, Lu C.
    BMC Cancer; 2019 Sep 05; 19(1):886. PubMed ID: 31488089
    [Abstract] [Full Text] [Related]

  • 39. Evaluation of the prognostic values of solute carrier (SLC) family 39 genes for patients with lung adenocarcinoma.
    Zhou H, Zhu Y, Qi H, Liang L, Wu H, Yuan J, Hu Q.
    Aging (Albany NY); 2021 Feb 01; 13(4):5312-5331. PubMed ID: 33535184
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 15.